SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-23-011433
Filing Date
2023-03-31
Accepted
2023-03-31 17:03:46
Documents
12
Period of Report
2023-03-27
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K janx-20230327.htm   iXBRL 8-K 57310
  Complete submission text file 0000950170-23-011433.txt   189885

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT janx-20230327.xsd EX-101.SCH 2471
3 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT janx-20230327_pre.xml EX-101.PRE 12070
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT janx-20230327_lab.xml EX-101.LAB 20062
6 EXTRACTED XBRL INSTANCE DOCUMENT janx-20230327_htm.xml XML 5113
Mailing Address 10955 VISTA SORRENTO PARKWAY SUITE 200 SAN DIEGO CA 92130
Business Address 10955 VISTA SORRENTO PARKWAY SUITE 200 SAN DIEGO CA 92130 (858) 751-4493
Janux Therapeutics, Inc. (Filer) CIK: 0001817713 (see all company filings)

IRS No.: 822289112 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40475 | Film No.: 23788989
SIC: 2834 Pharmaceutical Preparations